Show simple item record

dc.contributor.authorShokraneh, Farhad
dc.date.accessioned2017-08-24T15:11:52Z
dc.date.available2017-08-24T15:11:52Z
dc.date.issued2016
dc.identifier.citationMansour-Ghanaei, R., Moradi-Lakeh, M., Shakerian, S., Karimi, A., Esmaeeli, S., Shokraneh, F., Mahmoudi, S. & Yaghoubi, M. (2016). Acellular pertussis vaccine efficacy: An updated systematic review and meta-analysis. Medical Journal of the Islamic Republic of Iran, 30, pp.451.
dc.identifier.urihttp://hdl.handle.net/20.500.12904/11738
dc.description© 2016 Iran University of Medical Sciences This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
dc.description.abstractBackground: Recent studies indicate an increased incidence of pertussis disease in recent years. The aim of this study was to evaluate the efficacy of the acellular vaccine for children (as a replacement of current whole cell vaccine in the Expanded Program on Immunization) and for high-risk adults in Iran through updating current best available evidence. Methods: We performed a systematic literature review in relevant databases we focused on previously published systematic reviews to select those that address our questions. The AMSTAR (assessing the methodological quality of systematic reviews) tool was used for screening available reviews. Then search in databases was done until Feb 2014 to update the evidence. We pooled results using meta-analysis methods by Stata statistical package. Results: Eleven systematic review articles were included in the initial evaluation. In the end, two systematic reviews on acellular vaccine booster doses and the acellular vaccine in children were selected as the baseline evidence. In the update phase, new clinical trials were screened, and the results were updated. Overall pooled estimate of relative efficacy of acellular to whole cell was 0.68 (95% CI, 0.55-0.81) for children immunization Pooled estimates for the efficacy of acellular versus placebo were 0.70 (95% CI, 0.60-0.80). Overall pooled estimate of efficacy of booster dose of acellular was 0.87(95% CI, 0.85-0.88) compared to placebo. In addition pooled estimate of acellular vaccine efficacy based on response to antigen was 0.78(95% CI, 0.64-0.93) in highrisk group. Conclusion: The results show higher performance and safety of the acellular vaccine in the prevention of pertussis in children versus the whole cell vaccine. Moreover, the efficacy of the acellular vaccine in high-risk adult groups is acceptable. This study provides evidence in favor of the introduction of an acellular vaccine to the national program of immunization. Studies on cost effectiveness and aspects of policy analysis are recommended.
dc.description.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419227/
dc.formatFull text uploaded
dc.subjectPertussis vaccine
dc.subjectWhooping cough
dc.titleAcellular pertussis vaccine efficacy: An updated systematic review and meta-analysis
dc.typeArticle
refterms.dateFOA2021-06-15T17:56:51Z


Files in this item

Thumbnail
Name:
Mansour-Ghanaei 2016 1-11.pdf
Size:
1.064Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record